Furthermore, a number of reports demonstrated that RAD51 is involved in resistance to anticancer treatments such as radiation and platinum chemotherapy agents in various tumor types, including lung cancer 14, 15, 19, 20, 26. This evidence concerns the gene RAD51 and neoplasm.